Stock CVKD CADRENAL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Cadrenal Therapeutics, Inc.

Equities

CVKD

US1276361086

Market Closed - Nasdaq
Other stock markets
 02:00:00 06/06/2024 am IST 		5-day change 1st Jan Change
0.5098 USD +6.21% Intraday chart for Cadrenal Therapeutics, Inc. +23.59% -31.10%
09/05 Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
09/04 Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts
Cadrenal Therapeutics Files $100 Million Mixed Shelf; Shares Fall
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Cadrenal Therapeutics Highlights Additional Need for A New Vitamin K Antagonist Following Updates from the Recent European Society of Cardiology Congress
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Cadrenal Therapeutics, Inc. Expands Focus for Tecarfarin to Patients with Implanted Medical Devices for Heart Diseases
Cadrenal Therapeutics Announces Appointment of Robert Lisicki to Board of Directors
Cadrenal Therapeutics Closes $7.5 Million Private Placement
Cadrenal Therapeutics to Raise $7.5 Million From Share Placement
Top Premarket Gainers
Cadrenal Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Cadrenal Therapeutics, Inc. Reports Earnings Results for the Eleven Months Ended December 31, 2022
Cadrenal Therapeutics, Inc. Announces Board Appointments
Cadrenal Therapeutics Gets Fast Track Label for Tecarfarin
Cadrenal Therapeutics Receives FDA Fast Track Designation for Tecarfarin for Prevention of Systemic Thromboembolism of Cardiac Origin in Patients with End-Stage Renal Disease and Atrial Fibrillation
Cadrenal Therapeutics, Inc. has completed an IPO in the amount of $7 million.
Cadrenal Therapeutics, Inc. has filed an IPO in the amount of $10 million.
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CVKD Stock
  4. News Cadrenal Therapeutics, Inc.
  5. Other languages